S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
Log in
NASDAQ:LNSR

LENSAR Stock Forecast, Price & News

$9.04
-0.01 (-0.11 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.02
Now: $9.04▼
$9.64
50-Day Range
$6.28
MA: $7.45▼
$9.56
52-Week Range
$3.16
Now: $9.04▼
$12.71
Volume24,785 shs
Average Volume44,028 shs
Market Capitalization$96.18 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
LENSAR, Inc. operates as a commercial-stage medical device company. It focuses on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company was incorporated in 2004 and is headquartered in Orlando, Florida.

Headlines

LENSAR Announces Presentations at American Academy of Ophthalmology Highlighting the Advantages of Streamline IV in Both Cataract and Astigmatism Corrective Surgery
February 24, 2021 |  finance.yahoo.com
LENSAR to Present at the 32nd Annual Piper Sandler Virtual Healthcare Conference
February 24, 2021 |  finance.yahoo.com
We Think LENSAR (NASDAQ:LNSR) Needs To Drive Business Growth Carefully
February 24, 2021 |  finance.yahoo.com
LENSAR Expands Board of Directors with the Appointments of Aimee S. Weisner and Elizabeth G. O’Farrell
February 24, 2021 |  finance.yahoo.com
LENSAR to Present at Two Upcoming Investor Conferences
February 24, 2021 |  finance.yahoo.com
Is LENSAR Inc. (LNSR) A Smart Long-Term Buy?
February 24, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LNSR
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.lensar.com
Phone888 536 7271
Employees75
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares10,639,000
Market Cap$96.18 million
Next Earnings Date3/1/2021 (Estimated)
OptionableNot Optionable

MarketRank™

Overall MarketRank™

1.70 out of 5 stars

Medical Sector

223rd out of 1,956 stocks

Surgical & Medical Instruments Industry

22nd out of 165 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$9.04
-0.01 (-0.11 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LNSR News and Ratings via Email

Sign-up to receive the latest news and ratings for LNSR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











LENSAR (NASDAQ:LNSR) Frequently Asked Questions

Is LENSAR a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LENSAR in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LENSAR stock.
View analyst ratings for LENSAR or view top-rated stocks.

What stocks does MarketBeat like better than LENSAR?

Wall Street analysts have given LENSAR a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but LENSAR wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is LENSAR's next earnings date?

LENSAR is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for LENSAR.

What price target have analysts set for LNSR?

1 Wall Street analysts have issued 1-year target prices for LENSAR's shares. Their forecasts range from $20.00 to $20.00. On average, they anticipate LENSAR's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 121.2% from the stock's current price.
View analysts' price targets for LENSAR or view top-rated stocks among Wall Street analysts.

Who are LENSAR's key executives?

LENSAR's management team includes the following people:
  • Mr. Nicholas T. Curtis, CEO & Director (Age 64, Pay $1.01M)
  • Mr. Alan B. Connaughton, Chief Operating Officer (Age 49, Pay $671.53k)
  • Mr. Randy W. Frey, Founder and Consultant (Age 63)
  • Mr. Thomas R. Staab II, Chief Financial Officer (Age 53)
  • Mr. Ron Goldrich, Sr. VP of Sales

Who are some of LENSAR's key competitors?

Some companies that are related to LENSAR include UFP Technologies (UFPT), Apyx Medical (APYX), InfuSystem (INFU), T2 Biosystems (TTOO), Utah Medical Products (UTMD), The Westaim (WEDXF), PAVmed (PAVM), Neuronetics (STIM), Soliton (SOLY), IRadimed (IRMD), RenovaCare (RCAR), TELA Bio (TELA), DarioHealth (DRIO), Isoray (ISR) and Titan Medical (TMDI).
View all of LNSR's competitors.

What is LENSAR's stock symbol?

LENSAR trades on the NASDAQ under the ticker symbol "LNSR."

How do I buy shares of LENSAR?

Shares of LNSR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LENSAR's stock price today?

One share of LNSR stock can currently be purchased for approximately $9.04.

How much money does LENSAR make?

LENSAR has a market capitalization of $96.18 million.

How many employees does LENSAR have?

LENSAR employs 75 workers across the globe.

What is LENSAR's official website?

The official website for LENSAR is www.lensar.com.

How can I contact LENSAR?

The company can be reached via phone at 888 536 7271 or via email at [email protected]


This page was last updated on 2/26/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.